Sorafenib: Experience and Better Manage­ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis

BACKGROUND: Sorafenib is the first-line treatment for advanced hepatocellular carcinoma (HCC). The management of its side effects is improving. This study aimed to assess, in real life, if this translates into a better prognosis. METHODS: This was a retrospective study of advanced HCC patients treat...

Full description

Saved in:
Bibliographic Details
Published in:Liver Cancer
Main Authors: Raoul, Jean-Luc, Adhoute, Xavier, Penaranda, Guillaume, Perrier, Hervé, Castellani, Paul, Oules, Valérie, Bourlière, Marc
Format: Artigo
Language:Inglês
Published: S. Karger AG 2019
Subjects:
Original Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6883434/
https://ncbi.nlm.nih.gov/pubmed/31799203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000497161
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items